Ocugen Adds Celairis As OCU400 Partner For Up To $7.1 Million Plus Sales Payments

The regional license adds royalties and a 50% gross-profit share, with trial results expected in the first quarter of 2027.

Share
Ocugen Adds Celairis As OCU400 Partner For Up To $7.1 Million Plus Sales Payments

Ocugen, which develops gene therapies for blinding eye diseases, signed a regional OCU400 license with Celairis Therapeutics on Tuesday worth up to $7.1 million in fees and potential milestones, plus payments tied to future sales, according to an SEC filing. The agreement adds a commercialization partner before planned approval applications for the investigational treatment.

Trial Results Gate Part Of Payment

Ocugen is eligible for up to $6.1 million through an upfront license fee and a payment dependent on positive results from OCU400's late-stage trial. A separate $1 million milestone depends on approval by Australia's Therapeutic Goods Administration.

Future sales would bring Ocugen royalties of under 10% on net sales, as well as 50% of the gross profits Celairis earns from those sales. The maximum fee-and-milestone amount therefore includes payments contingent on clinical and regulatory outcomes.

Sydney-based Celairis, a biopharmaceutical company that licenses, develops and commercializes medicines, will handle regulatory applications, market access and commercialization. Its exclusive territory covers Australia, New Zealand, Singapore, Malaysia, Thailand, the Philippines, Vietnam and Indonesia; the partners can agree to add other countries in Asia and Oceania.

Ocugen retains the exclusive right to manufacture OCU400 and will own its global safety database. The partners aim to negotiate a manufacturing and supply agreement within 90 days of signing.

An Eye Therapy Awaiting Approval

OCU400 targets retinitis pigmentosa, inherited retinal diseases that progressively damage vision and can cause blindness. Ocugen said the treatment remains unapproved, unregistered and unavailable for supply throughout the licensed territory.

The company's modifier gene therapy platform delivers nuclear hormone receptor genes to the retina. OCU400's late-stage trial has completed enrollment of 140 participants. Ocugen also is developing OCU410 for geographic atrophy, an advanced form of dry age-related macular degeneration, and OCU410ST for Stargardt disease.

Ocugen expects OCU400 results in the first quarter of 2027. It plans U.S. and European approval applications afterward, with applications in the Celairis territory expected to follow.

A Regional Network Before Launch

Ocugen Chairman, CEO and Co-Founder Shankar Musunuri described the deal as its “third strategic regional partnership for OCU400.” He said local partnerships are critical to the company's goal of reaching patients globally.

The Celairis agreement joins a Middle East and North Africa license with Roots Pharmaceutical that followed an agreement with Kwangdong Pharmaceutical in South Korea. The Roots deal carries up to $255 million in potential sales milestones.

Ocugen has completed manufacturing qualification batches intended to support its U.S. approval application and commercial supply. In Wednesday's business update, it reported $84.6 million in cash and investments and projected that its funding would last into 2028.

The next clinical checkpoint is the expected first-quarter 2027 OCU400 readout—the result on which part of the Celairis payment depends.

Sources

More on Ocugen

All Ocugen (OCGN) coverage →